CD40 and neoplasm: Indeed, a phase I clinical trial enrolling patients with locally advanced or metastatic melanoma and breast cancer highlighted the importance of optimizing Fc portion of CD40 agonistic antibodies in order to achieve meaningful clinical anti-tumour effects, and the use of species-matched Fc receptor models to accurately estimate appropriate drug dosage (76).